FY2025 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 EPS estimates for Xenon Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will earn ($3.80) per share for the year, down from their prior estimate of ($2.85). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.13) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals' FY2026 earnings at ($5.00) EPS, FY2027 earnings at ($3.15) EPS and FY2028 earnings at ($2.45) EPS.

Several other analysts have also recently issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright restated a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Finally, Raymond James reiterated an "outperform" rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $56.00.

Xenon Pharmaceuticals Trading Up 0.9 %

XENE stock traded up $0.37 during midday trading on Friday, reaching $39.92. The stock had a trading volume of 271,327 shares, compared to its average volume of 410,964. The company's fifty day simple moving average is $40.26 and its 200 day simple moving average is $40.75. The company has a market cap of $3.04 billion, a price-to-earnings ratio of -14.16 and a beta of 1.20. Xenon Pharmaceuticals has a 52-week low of $35.53 and a 52-week high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.01. During the same period in the previous year, the firm earned ($0.73) earnings per share.

Institutional Trading of Xenon Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in shares of Xenon Pharmaceuticals by 2.2% in the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company's stock valued at $272,349,000 after purchasing an additional 149,511 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Xenon Pharmaceuticals by 0.4% during the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company's stock worth $151,317,000 after purchasing an additional 15,226 shares during the period. Braidwell LP grew its position in shares of Xenon Pharmaceuticals by 5.7% during the third quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company's stock worth $106,585,000 after acquiring an additional 146,682 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Xenon Pharmaceuticals by 144.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock worth $100,506,000 after buying an additional 1,507,135 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after purchasing an additional 905,129 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the company's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the transaction, the director now owns 23,573 shares in the company, valued at $968,378.84. This represents a 17.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ian Mortimer sold 22,468 shares of the firm's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,383 shares of company stock worth $2,535,891 over the last quarter. 5.52% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.